



*Imaging biomarkers are the key to detecting and treating cancer*

Press Release

**New €230K contract signed  
with a leading global biopharmaceutical company**

*MEDIAN Technologies will deploy its LMS applications on 20 sites in Europe and the US,  
as part of a Phase I study on patients with undifferentiated malignant solid tumors*

**Sophia Antipolis, France – October 7, 2013** – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a new €230K firm contract with one of its top 10 biopharmaceutical company client.

In this project, imaging data will be acquired in 20 clinical sites, located in Europe and in the US for a total of 70 patients enrolled. The project will start immediately.

*“Signing a second contract with this global biopharmaceutical company is of prime importance to us and demonstrates the growing interest of biopharmaceutical companies regarding our cutting-edge technology. During the trial, MEDIAN LMS – Lesion Management Solutions- will be deployed directly at investigator sites and will enable to decrease image interpretation variability among readers and provide the biopharmaceutical sponsor with more rapid access to imaging data as well. Sites will benefit from MEDIAN LMS technology to assess the evolution of tumor volume, an advanced imaging biomarker, enabling a better evaluation of patient response to therapy”,* said Nicolas Dano, Director of Business Development Europe and Asia.

As a reminder, MEDIAN Technologies announced on Sept. 26 the signing of a new contract with another of its top 10 biopharmaceutical company client. *“Our company is now sustaining its positioning toward major global biopharmaceutical companies”,* added Jerome Windsor, VP Pharma Business at MEDIAN.

Since the beginning of 2013, MEDIAN Technologies has recorded €3.9M (eq. \$5.3M) of orders, including €1.0M of firm orders and €2.9M of project awards [\*].

*[\*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.*



**About MEDIAN Technologies:** MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in



*Imaging biomarkers are the key to detecting and treating cancer*

Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Quintiles, to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary.

For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

## CONTACTS

### **MEDIAN Technologies**

Fredrik Brag, CEO

+33 492 906 582

[fredrik.brag@mediantechnologies.com](mailto:fredrik.brag@mediantechnologies.com)

### **Press**

#### **ALIZE RP**

Caroline Carmagnol

+ 33 664 189 959

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Christian Berg

+ 33 170 225 386

[christian@alizerp.com](mailto:christian@alizerp.com)

### **Investors**

#### **ACTIFIN**

Anaïs de Scitivaux

+ 33 156 881 114

[adescitivaux@actifin.fr](mailto:adescitivaux@actifin.fr)